|
|
|
| Effect of Simvastatin with Different Doses on Serum sE-Selectin and sICAM-1 Levels in Patients with Hyperlipidemia |
| CHEN Siwen, CHEN Yarong |
| Department of Neurology,Tongchuan City People's Hospital,Tongchuan Shaanxi 727031 |
|
|
|
|
Abstract 【Objective】To explore the effects of different doses of simvastatin on the levels of soluble E-selectin(sE-Selectin) and soluble intercellular adhesion molecule-1(sICAM-1) in the serum of patients with hyperlipidemia. 【Methods】A total of 80 patients with hyperlipidemia were divided into two groups based on differently used dosage of simvastatin with each group of 40 patients. The control group was given a conventional dose(20 mg/d),while the observation group received a high dose(40 mg/d) treatment. The clinical efficacy,lipid profiles [total cholesterol(TC),triglyceride(TG),high-density lipoprotein cholesterol(HDL-C),and low-density lipoprotein cholesterol(LDL-C)],serum levels of sE-Selectin and sICAM-1,and the incidence of adverse reactions were compared between the two groups. 【Results】The total effective rate in the observation group was 92.50%(37/40),which was significantly higher than the 75.00%(30/40) in the control group(P<0.05). After treatment,the TG,TC,LDL-C levels of both groups were lower than before treatment,and HDL-C levels were higher than before treatment(P<0.05). Furthermore,the TG,TC,and LDL-C levels in the observation group were lower,and the HDL-C levels were higher than those in the control group(P<0.05). After treatment,the serum sE-Selectin and sICAM-1 levels in both groups were lower than before treatment(P<0.05),with the levels in the observation group being significantly lower than those in the control group(P<0.05). The overall incidence of adverse reactions in both groups showed no significant difference (P>0.05). 【Conclusion】Compared to the conventional dosage,the high dose of simvastatin treatment for hyperlipidemia has a more remarkable therapeutic effect and better lipid-lowering results.
|
|
Received: 03 August 2022
|
|
|
|
|
|
[1] JR A G,MOON J. Pitavastatin for the treatment of primary hyperlipidemia and mixed dyslipidemia[J].Exp Rev Cardiovasc Ther,2010,8(8):1079-1090.
[2] 吴颖,严娟,艾炳蔚.调脂通络方联合辛伐他汀胶囊治疗高脂血症的临床研究[J].时珍国医国药,2017,28(3):651-652.
[3] REN Z,ZHAI J,HAN N,et al. The progress and related pharmacological mechanism of hyperlipidemia treatment[J].Asian Tradit Med,2019,14(6):268-279.
[4] 中国成人血脂异常防治指南修订联合委员会. 中国成人血脂异常防治指南(2016年修订版)[J].中华健康管理学杂志,2017,11(1):7-28.
[5] 古丽巴合提.扎卡力亚.不同剂量辛伐他汀治疗老年高脂血症的临床研究[J].白求恩军医学院学报,2012,10(2):104-105.
[6] DIXON D L,DONOHOE K L,OGBONNA K C,et al. Current drug treatment of hyperlipidemia in older adults[J].Drugs Aging,2015,32(2):127-138.
[7] 罗斌,梁碧涛.不同剂量辛伐他汀治疗老年高脂血症的疗效对比[J].中国老年学杂志,2012,32(11):2370-2371.
[8] 何娟,沈浓儿,黄炜,等.不同剂量的辛伐他汀治疗高脂血症的临床观察[J].中国药房,2015,26(9):1194-1196.
[9] 刘富春,王国威,宋航,等.辛伐他汀剂量对老年高脂血症患者疗效与安全性的影响[J].重庆医学,2014,43(9):1088-1089.
[10] 侯全基,张倢,谭荣任.不同剂量阿托伐他汀与辛伐他汀用于老年冠心病合并高脂血症治疗的临床效果比较[J].海南医学,2016,27(11):1756-1758.
[11] 董胜翔,牟宝华,韩桂英.辛伐他汀治疗老年高脂血症合并高血压的最佳剂量研究[J].实用药物与临床,2014,17(1):98-100.
[12] 韦之富,郭姣,荣向路,等. 高剂量辛伐他汀治疗48例老年高脂血症的临床效果[J].实用临床医药杂志,2016,20(7):158-159. |
|
|
|
2023, Vol. 40 
